Valeant Announces Q2 2017 Financial Results Date And Conference Call Details

LAVAL, Quebec, July 10, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX) (TSX: VRX) today announced that it plans to release second quarter 2017 financial results on Tuesday, Aug. 8, 2017. The Company will host a conference call and live webcast at 8:00 a.m. EDT to discuss the results and provide a business update. All materials will be made available on the investor relations portion of the corporate website before the start of the conference call.

Conference Call Details

 

Date

 

Tuesday, Aug. 8, 2017

Time

8:00 a.m. EDT

Webcast

http://ir.valeant.com/events-and-presentations

Participant Event Dial-in 

(877) 876-8393 (North America)


(443) 961-0178 (International) 

Participant Passcode

35736021

Replay Dial-in

(855) 859-2056 (North America)


(404) 537-3406 (International) 

Replay Passcode

31833 (replay available until Oct. 8, 2017)

About Valeant
Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at www.valeant.com.

Valeant Pharmaceuticals International, Inc. (PRNewsFoto/Valeant Pharmaceuticals International, Inc.) (PRNewsFoto/)

 

Investor Contacts:



Arthur Shannon                                    

Elif McDonald                     


arthur.shannon@valeant.com              

elif.mcdonald@valeant.com  


514-856-3855                                        

514-856-3855 


877-281-6642 (toll free)                         

877-281-6642 (toll free) 


Media Contact:  


Lainie Keller  


lainie.keller@valeant.com   


908-927-0617  


 

View original content with multimedia:http://www.prnewswire.com/news-releases/valeant-announces-q2-2017-financial-results-date-and-conference-call-details-300485451.html

SOURCE Valeant Pharmaceuticals International, Inc.

Back to news